Physiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, USA, Nov. 27-29, 2023. This unique preclinical model will be presented during the poster session on November the 28th at 2:30pm by Dr. François Briand, our Director of Research and Business Development.
Unlike mouse and rat, the obese hamster has a human-like lipoprotein/bile acids profile, shows evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis, and has a high preference for alcohol, which makes an excellent model of MetALD, which describes patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who consume greater amounts of alcohol per week.
Reach out to François Briand during the meeting to learn how Physiogenex animal models and CRO services will drive your preclinical development of drugs targeting metabolic diseases to success.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.